mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in...

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Recent advances in cancer therapy include small-molecule kinase inhibitors and monoclonal antibodies.
• Tumor mutations can significantly impact cancer drug sensitivity, but the precise relationship remains unclear.
• Understanding tumor genomic profiles is crucial for predicting treatment effectiveness.

Purpose of the Study:

• To introduce the Mutation To Cancer Therapy Scan (mTCTScan) web server for systematically analyzing mutation-cancer drug sensitivity.
• To provide a platform that leverages current knowledge and large-scale screening data for mutation-drug association analysis.
• To aid researchers and clinicians in interrogating mutation-dependent drug responses for precision oncology.

Main Methods:

• Developed mTCTScan by integrating the latest knowledge on mutation-cancer drug sensitivity associations.
• Utilized results from large-scale chemical screening of human cancer cell lines.
• Implemented an evidence-based scoring scheme to prioritize mutations and classify drug/compound sensitivity.
• Incorporated filtering functions and cancer-related annotations for comprehensive analysis.

Main Results:

• mTCTScan systematically analyzes mutations affecting cancer drug sensitivity based on individual genomic profiles.
• The platform prioritizes mutations and classifies related drugs/compounds based on integrative evidence and genomic context.
• mTCTScan facilitates the interpretation of mutation effects on drug response.

Conclusions:

• mTCTScan is a valuable tool for researchers and clinicians in the field of cancer precision medicine.
• The web server aids in understanding the mechanisms of mutation-dependent drug response.
• This platform has the potential to significantly impact personalized cancer treatment strategies.